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more episodes of syncope were studied. 
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secu,uve occasions by head-up tilt testing. Failure to repro- 
duce syncope or presyncope duting testing excluded the 
patient from the trial, The study design was approved by the 
University of Western Ontario Review Board for Health 
Sciences Research Involving Human Subjects. All partici- 
patus gave verbal and written informed consent. 
~bs. A physical and 
ne ination, electrocardiogram (ECG), ambulae 
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to decrease the sin 2%% The maximat 
min. The totd dur~+ 
a&up tilt was 30 min. The specificity and 
of this protocol have been desclibed clse- 
. Thirty minutes afkr two consecu- 
a&r the tilt test was 
Study medication for 1 week, the patients 
@efned fsr chltkd assessment, serum plasma disop;rra- 
e kel determination a d repeat head-up tilt testing. 
After 1 week d wasbut, the pat s were smsscd over to 
asss@ssed in the same 
I week of therapy.. Drug compliance was assessed 
The null hypothesis for primary anallysis was that intra- 
venous disopyramide would result in a ~50% reduction i  
syncope. For a twoQiled alpha error of 0 
power (beta = 0.2) of rejecting the null 
sample was estimated torequire Pi patients 
ment arm. This sample size was calculated by assuming that 
95% of the patients randomized to receive piacebo would 
have syncope provoked by head-up tilt testing. 
Similarly the secondary analysis, comprising the oral 
phase of the study, was to rej t the same null hypothesis 
proposed in the intravenous ase. Because all patients 
randomized were crossed ov receipt of placebo and 
disopyramide, the sample size was estimated torequire only 
II patients in total to de a 50% reduction in 
neurally mediated syncope iasi 
the primary analysis (alpha = 0.05, beta = 0.2). 
SMstkal anal~&~ Groups were compared by the chi- 
square test or Fisher exact test for categoric variables. 
Continuous variables were compared .4ith paired or tin- 
paired t tests where propriate. A 95% confidence kterval 
was constructed ab 
the interval corMEd the sp 
tinuuus variables were reported 
s. Chid findhgs, Twelve men and 10 
ean age of 32 2 17 years were ruxuited 
between February 1990 through arch 1!N2. Batien1.s had 
hadamean(?-SI)of lli + 11 syn pal spells before referral 
(range 2 to 64). Electrophysiologic study performed in 1% 
patients did not provide any addi al information regarding 
the cause of syncope, The echoc o&ram was normal in all 
patients. No patient had evide f noderlying structural 
heart disease, 
Baseline head-up tilt respcme (T&T I), A positive 
response during two consecctive til! tests q;\ras achieved 
without isoproterenol infusion ia 12 patients. lsoproterenol 
was infused in another four patients, In the remaining six 
patients, an isoprotercnol infusion was necessary toprovoke 
syncope during one of the two consecutive tilt tests. The 
mean dose of isoproterenol was 1.4 c 0.5 
2.5). No significant differences inheart rate, mean arterial 
blood pressure or time of onset of presyncope orsyncope 
were observed between the first and second tilt tests. 
~nndraverauus placebo wsus ~is~~y~~~i~~ (T&Yes 2 arrd 
.?). A significant reduction i the o 
tilt test result) 
no significant 
time of syncope onset (12 ? 7.2 mi 
onset after randomi 
(12.9 2 8.4 min) or 
isopyramidc plasma Ievels in the group assigned to the 
active medication were 9.68 2 2.3 ~mo~~iter (tbe~~e~t~c 
range 8,7 to 14.7). 
Table 3 shows the response tobead= 
15 patients who completed crossover. 
tion in preventing syncope wds achieved. A positive head-up 
tilt test response was elicited i I2 WOTO~ of the f 5 patients 
randomized to disopyramide a in 13 (87%) of the patients 
randomized to placebo, All p nts initially randorkzed to
receive ither placebo (n = 9) isopyramide (a = ;Pi bad a 
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3. Outcome ofPatients With Complete Cross Over During 
Up Tat Testing: Intravenous Place&o Versus Disopyrarnide 
7U-t Test 
Placebo Disopyramide 
kspmge No. % No. % 
Fositive I3 87 12 80 
ve 2 13 3 20 
Fisk ewct lest, p = 0.50 (mean disopymmide l vel was 9.68 f 
2.3 ~IIKGI~x; th~age~tk EXIT 8.7 60 14.7). 
After cwsstrver, four 
pe were reported during both 
twnts, and these pisodes were assaci- 
ated with induction of syncspe during head-up tilt tcstin 
one patient, One additional patient had seven presync 
pknts received bath treatments, i?t 
Fiir exact est, p = 
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either intravenous 0rural d~s~~y~ 
the 27 patients who received place 
OnSc JO SWkl ~~~~~-~U~ tilt tests
enrolled in the study hai three eo 
ed by 20 rnin (two to meet study entry criteria plus 
One in the first i 
elicited after the th 
derwent tilt testing for a fourth 
alogic therapy. Syncape re- 
curred in three patients receiving disopyramide and 
three patients (30%) receiving placebo (p 
mide was discontinued in eight patients 
adverse ffects. Urinary hesitancy, dry mouth and gastroin- 
testinal intolerance were the most frequently reported ad- 
verse ffects. The remaining three patients were continued 
Therapy No Therapy 
(n = 11) (n = 10) 
No. % No. % 
Follow-up duration @IO) 24.5 + 8.3 30.3 k 7.2* 
Patients 
With syncope 3 27 3 30* 
With presyncope 4 36 4 40’ 
*p > 0.05, Fisher exact est. 
io receive placebo continued to have a positive head-up tih 
test response. Because ou was based on the 
ption that therapy isopyramide would 
the induction of syn % (&9), this finding 
was unexpected, and the explanation for it is unclear. 
Previous tudies (29) have reported a striking spontaneous 
reduction in the recurrence of syncope in patients without 
structural heart disease. Our findings are concordant with a 
recently published controlled trial (26) using various thera- 
peutic interventions for the management of tilt-induced 
neurally mediated syncope. That study (26) was unable to 
document a significant difference between therapy and pla- 
cebo. Likewise, recurrence of syncope in the treated group 
as well as in t&e growp rando d to placebo was low (20% 
and 27%, respectively) (26). findings uggest that eval- 
uation of therapeutic efficacy solely on the basis of the 
results of head-up tilt testing may ‘be misleading because of
the marked reduction in the incidence of positive tilt test 
results over time, as well as the low recurrence rate of 
syncope in both the treated and untreated groups. The use of 
disopyramide in patients with neurally mediated syncope is 
reassurance an
a positive tilt test response after an intervention were cr 
over to the ahernative treatment (Fig- 1). ~o~~thefess, 
the data were amalyzed xamining allpatients who achieved a 
negative tilt test result (a “positive” therapeutic res 
no difference b tween therapy and placebo. 
s. Intravenous disopyramide was clearly inef- 
fective for the prevention of syncope. The effects of oral 
disopyramide w re overshadowed by the striking decrease 
in the incidence ofpositive test results with either interven- 
tion as the protocol progressed. Recurrence of syncope after 
investigative protocol was infrequent 
ow-up regardless of treatment group. The 
utic interventions assdssed solely by the re 
d-up tilt testing should be i~te~reted with 
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